WO2012085927A2 - Tadalafil compositions - Google Patents
Tadalafil compositions Download PDFInfo
- Publication number
- WO2012085927A2 WO2012085927A2 PCT/IN2011/000820 IN2011000820W WO2012085927A2 WO 2012085927 A2 WO2012085927 A2 WO 2012085927A2 IN 2011000820 W IN2011000820 W IN 2011000820W WO 2012085927 A2 WO2012085927 A2 WO 2012085927A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tadalafil
- pharmaceutically acceptable
- solid dispersion
- dispersion
- excipient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Definitions
- the invention relates to tadalafil compositions comprising tadalafil or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient, wherein said composition comprises a solid dispersion of crystalline tadalafil.
- the invention also relates to process of preparing a solid dispersion of crystalline tadalafil and compositions of tadalafil comprising the same.
- Tadalafil is a cyclic guanosine monophosphate ("cGMP") specific phosphodiesterase type 5 (“PDE5") inhibitors. It is indicated for the treatment of erectile dysfunction in men and pulmonary hypertension. Tadalafil has a much longer duration of action because of its longer half-life (17.5 hr) than other PDE5 inhibitors like either sildenafil or vardenafil (4-5 hr). it is marketed in the US under the brand name of Cialis® and Adcirca® by Eli Lilly.
- Tadalafil is practically insoluble in water and very slightly soluble in ethanol. Because of its insoluble nature, conventional formulations of tadalafil exhibit very poor dissolution rate and bioavailability. Thus, it is required to increase the dissolution rate and bioavailability of the drug for faster and quicker onset of action.
- a number of methods have been developed to increase the bioavailability of poorly soluble drugs like tadalafil which includes use of surfactants, particle size reduction, inclusion complexation and different solid dispersion methods.
- US5985326 relates to solid dispersions of poorly soluble drugs like tadalafil and its use in pharmaceutical compositions.
- US7182958 relates to composition comprising tadalafil wherein the bioavailability is enhanced by milling the active ingredient so that D 90 of the active ingredient is less than 40 microns.
- US20070104792 relates to compositions comprising nanoparticulate tadalafil, or a salt or derivative thereof, having improved bioavailability, faster rates of absorption and a faster onset of therapeutic effect.
- US20080009502 and US20100099687 relate to solid composites including tadalafil and at least one carrier, wherein at least about 85 wt % of the tadalafil is in intimate association with the at least one carrier.
- at least 85 wt % of the tadalafil is not in crystalline form.
- solid dispersion technique is employed to enhance the solubility and dissolution.
- This enhanced solubility and dissolution is by virtue of the drug being in the amorphous state in said dispersion which has increased solubility and dissolution as compared to crystalline form due to difference in thermodynamic properties.
- this conversion in phase may affect the stability as well as quality and purity of the product.
- the present inventors have been successful in preparing a solid dispersion of tadalafil, wherein tadalafil remains crystalline in nature, as well as the composition comprising said dispersions also remains crystalline.
- Figure 1 illustrates an XRPD pattern of crystalline tadalafil active ingredient.
- Figure 2 illustrates an overlay of the XRPD pattern of crystalline tadalafil active ingredient, placebo and the solid composite.
- Figure 3 illustrates an overlay of the XRPD pattern of crystalline tadalafil active ingredient, placebo and the tablet.
- the invention relates to tadalafil compositions comprising tadalafil or its pharmaceutically acceptable salts thereof and atleast one or more pharmaceutically acceptable excipient, wherein the composition comprises a solid dispersion of crystalline tadalafil.
- the invention also relates to process of preparing a solid dispersion of crystalline tadalafil and composition of tadalafil comprising solid dispersion.
- the invention provides solid dispersion of tadalafil or its pharmaceutically acceptable salts thereof and optionally other pharmaceutically acceptable excipients, wherein said tadalafil is substantially in crystalline state.
- the invention provides compositions comprising solid dispersion of tadalafil or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient, wherein said dispersion comprises tadalafil in substantially crystalline state.
- the invention relates to a process of preparing a solid dispersion of crystalline tadalafil or its pharmaceutically acceptable salts thereof.
- the invention relates to a process of preparing compositions of tadalafil comprising solid dispersion of crystalline tadalafil or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient.
- the invention also provides an invitro drug dissolution profile of the composition prepared according to the invention which comparatively matches with the commercially available Cialis ® .
- the invention relates to solid dispersion of tadalafil or its pharmaceutically acceptable salts thereof and optionally other pharmaceutically acceptable excipients, wherein said tadalafil is substantially in crystalline state.
- the invention also relates to tadalafil compositions comprising tadalafil or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient, wherein said solid dispersion comprises tadalafil in substantially crystalline state.
- the invention also relates to a process of preparing a solid dispersion of crystalline tadalafil and composition of tadalafil comprising solid dispersion.
- compositions refers to dosage form for oral administration in the form of tablets, capsules, pills, powders, granules, particles, pellets, beads, or mini-tablets.
- dispersion or “solid dispersion” as used herein is defined as a system in a solid state that comprises at least two components, wherein one component is dispersed substantially evenly throughout the other component or components. It may be used interchangeably and synonymously for "pre-mix” or “admixture” or “composite” or “solid composite” to name a few.
- crystalline means having a physical state that is a regular three-dimensional array of atoms, ions, molecules or molecular assemblies.
- amorphous means a physical state without having regular arrangement of atoms, ions, molecules or molecular assemblies i.e., an unorganized structure.
- substantially crystalline state refers that recognizable characteristic crystalline tadalafil peaks are present in an X-ray powder diffraction pattern of the solid dispersion and/ or the compositions containing said solid dispersion.
- Solid dispersion is a well known method for enhancement of solubility and dissolution of poorly soluble drugs.
- the solid dispersion of the present invention may be prepared by a number of techniques including solvent evaporation, melt adsorption, fusion, spray drying, spray granulation, spray freezing, spray congealing, melt extrusion, and supercritical fluid precipitation etc.
- preferred method of preparing the solid dispersion comprising tadalafil and atleast one pharmaceutical excipient is by spray granulation or solvent evaporation technique.
- the method involves atomization of the feed solution or suspension in the chamber of a fluid bed-type processor or a pan-coater which is charged with inert filler material. During drying the -filler becomes agglomerated and/or coated and/or layered by the in-situ formation of the solid dispersion by evaporation or spray-drying of the feed solution or dispersion comprising tadalafil. Either of the bottom spray mode or a top spray mode can be used.
- the solid dispersion prepared according to an embodiment of the invention is formulated in to suitable dosage forms by methods known in the art.
- composition according to an embodiment of the invention in addition to the active ingredient may comprise one or more pharmaceutically acceptable excipients which include, but are not limited to diluents, lubricants, binders, surfactants, film-formers, plasticizers, coloring agents, flavoring agents, sweetening agents, preservatives, antioxidants and the like.
- Diluents used include, but not limited to microcrystalline cellulose (MCC), silicified MCC, lactose, starch, pregelatinized starch, mannitol, sorbitol, dextrates, dextrin, calcium carbonate, calcium sulfate, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, magnesium carbonate, magnesium oxide and the like.
- Binders used include, but not limited to acacia, alginic acid, carbomer copolymer, carbomer interpolymer, copovidone, microcrystalline cellulose, dextrin, ethylcellulose, gelatin, glucose (liquid), guar gum, hydroxypropyl cellulose, maltose, methylcellulose, polyethylene oxide, polyvinylpyrrolidone, povidone, starch, or sodium carboxymethylcellulose and the like.
- Surfactants used include, but not limited to (a) nonionic surfactants such as polyoxyethylene fatty alcohol ethers, sorbitan fatty acid esters, polyoxyethylene fatty acid esters, sorbitan esters, glycerol monostearate, polyethylene glycols, cetyl alcohol, cetostearyl alcohol, stearyl alcohol, poloxamers, polaxamines (b) anionic surfactants such as potassium laurate, triethanolamine stearate, sodium lauryl sulfate, alkyl polyoxyethylene sulfates, dioctyl sodium sulfosuccinate, negatively charged phospholipids and negatively charged glyceryl esters (c) cationic surfactants such as quaternary ammonium compounds, benzalkonium chloride, cetyltrimethylammonium bromide, chitosans and lauryldimethylbenzylammonium chloride.
- Lubricants used include, but not limited to colloidal
- Suitable solvents that may be used for preparing the dispersion include organic, aqueous, or a mixture thereof.
- Organic solvents may be aliphatic alcohols such as methanol, ethanol, n-propanol, and isopropanol; aliphatic ketones such as acetone and methyl ethyl ketone; aliphatic carboxylic esters such as ethyl acetate; aromatic hydrocarbons such as toluene and xylene; aliphatic hydrocarbons such as hexane; aliphatic nitriles such as acetonitrile; chlorinated hydrocarbons such as dichloromethane; aliphatic sulfoxides such as dimethyl sulfoxide; and the like, as well as mixtures comprising at least one of the foregoing organic solvents.
- Aqueous solvents include solvent comprising water and/or a water-miscible organic solvent such as a lower alcohol, acetonitrile, tetrahydrofuran, dimethylacetamide, dimethyl formamide, and the like. Combination of various solvents can also be used.
- the tablets may be optionally coated with a film former that comprises polymers such as cellulose derivatives or other commercially available coating compositions such as InstacoatTM, OpadryTM etc.
- a film former that comprises polymers such as cellulose derivatives or other commercially available coating compositions such as InstacoatTM, OpadryTM etc.
- the invention also relates to process for preparing tadalafil compositions comprising crystalline tadalafil solid dispersion or its pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient, wherein, said process comprises the steps of: i) Preparing granulate comprising tadalafil dispersion along with at least one filler and optionally other excipients, by wet granulation; ii) Drying said granulate;
- step (iii) Blending said granulate of step (ii) with extra-granular excipient; iv) Compressing said blended granulate of step (iii) to get the tablet;
- Determination of phase conversion of tadalafil either in pure form or in the pharmaceutical compositions comprising the dispersions of said drug can be determined by using analytical techniques like X-ray diffraction analysis, differential scanning calorimetry, optical microscopy etc.
- the invention uses X- ray diffraction analysis to determine the physical form of the drug in pure form as well as in the composition.
- step-1 Add poloxamer to step-1 under stirring.
- step-3 granulates and blends.
- step-2 dispersion in Fluid bed processor.
- step-3 Granulate lactose using step-2 dispersion in Fluid bed processor.
- step-3 Granulate lactose using step-2 dispersion in Fluid bed processor.
- step-3 Granulate lactose using step-2 dispersion in Fluid bed processor.
- Example 2 & 3 The composition as disclosed in Example 2 & 3 comprising the dispersion of crystalline tadalafil were studied for drug release in 1000 ml of aqueous media, containing 0.25 wt% sodium lauryl at 37°C, USP apparatus II (paddle) rotating at a speed of 25 rpm; and the results are tabulated in Table 1 given below:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to tadalafil compositions comprising tadalafil or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient, wherein the composition comprises a solid dispersion of crystalline tadalafiL The invention also relates to process of preparing a solid dispersion of crystalline tadalafil and composition of tadalafil comprising solid dispersion.
Description
TADALAFIL COMPOSITIONS
FIELD OF INVENTION
The invention relates to tadalafil compositions comprising tadalafil or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient, wherein said composition comprises a solid dispersion of crystalline tadalafil. The invention also relates to process of preparing a solid dispersion of crystalline tadalafil and compositions of tadalafil comprising the same.
BACKGROUND OF THE INVENTION AND RELATED PRIOR ARTS Tadalafil is a cyclic guanosine monophosphate ("cGMP") specific phosphodiesterase type 5 ("PDE5") inhibitors. It is indicated for the treatment of erectile dysfunction in men and pulmonary hypertension. Tadalafil has a much longer duration of action because of its longer half-life (17.5 hr) than other PDE5 inhibitors like either sildenafil or vardenafil (4-5 hr). it is marketed in the US under the brand name of Cialis® and Adcirca® by Eli Lilly.
Tadalafil is practically insoluble in water and very slightly soluble in ethanol. Because of its insoluble nature, conventional formulations of tadalafil exhibit very poor dissolution rate and bioavailability. Thus, it is required to increase the dissolution rate and bioavailability of the drug for faster and quicker onset of action. A number of methods have been developed to increase the bioavailability of poorly soluble drugs like tadalafil which includes use of surfactants, particle size reduction, inclusion complexation and different solid dispersion methods.
US5985326 relates to solid dispersions of poorly soluble drugs like tadalafil and its use in pharmaceutical compositions.
US7182958 relates to composition comprising tadalafil wherein the bioavailability is enhanced by milling the active ingredient so that D90 of the active ingredient is less than 40 microns.
US20070104792 relates to compositions comprising nanoparticulate tadalafil, or a salt or derivative thereof, having improved bioavailability, faster rates of absorption and a faster onset of therapeutic effect.
US20080009502 and US20100099687 relate to solid composites including tadalafil and at least one carrier, wherein at least about 85 wt % of the tadalafil is in intimate association with the at least one carrier. Preferably, at least 85 wt % of the tadalafil is not in crystalline form.
It is well known in the art that, solid dispersion technique is employed to enhance the solubility and dissolution. This enhanced solubility and dissolution is by virtue of the drug being in the amorphous state in said dispersion which has increased solubility and dissolution as compared to crystalline form due to difference in thermodynamic properties. However, this conversion in phase may affect the stability as well as quality and purity of the product. It is quite difficult to make a solid dispersion wherein, the drug retains its original form during its further processing as well as during the shelf-life, of the formulation containing said dispersion. The present inventors have been successful in preparing a solid dispersion of tadalafil, wherein tadalafil remains crystalline in nature, as well as the composition comprising said dispersions also remains crystalline.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1 illustrates an XRPD pattern of crystalline tadalafil active ingredient. Figure 2 illustrates an overlay of the XRPD pattern of crystalline tadalafil active ingredient, placebo and the solid composite.
Figure 3 illustrates an overlay of the XRPD pattern of crystalline tadalafil active ingredient, placebo and the tablet.
SUMMARY AND OBJECTIVES OF THE INVENTION
The invention relates to tadalafil compositions comprising tadalafil or its pharmaceutically acceptable salts thereof and atleast one or more pharmaceutically acceptable excipient, wherein the composition comprises a solid dispersion of crystalline tadalafil. The invention also relates to process of preparing a solid dispersion of crystalline tadalafil and composition of tadalafil comprising solid dispersion.
In one embodiment, the invention provides solid dispersion of tadalafil or its pharmaceutically acceptable salts thereof and optionally other pharmaceutically acceptable excipients, wherein said tadalafil is substantially in crystalline state.
In another embodiment, the invention provides compositions comprising solid dispersion of tadalafil or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient, wherein said dispersion comprises tadalafil in substantially crystalline state.
In further embodiment, the invention relates to a process of preparing a solid dispersion of crystalline tadalafil or its pharmaceutically acceptable salts thereof.
In yet another embodiment, the invention relates to a process of preparing compositions of tadalafil comprising solid dispersion of crystalline tadalafil or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient.
The invention also provides an invitro drug dissolution profile of the composition prepared according to the invention which comparatively matches with the commercially available Cialis®.
DETAILED DESCRIPTION OF THE EMBODIMENTS OF THE INVENTION
The invention relates to solid dispersion of tadalafil or its pharmaceutically acceptable salts thereof and optionally other pharmaceutically acceptable excipients, wherein said tadalafil is substantially in crystalline state.
The invention also relates to tadalafil compositions comprising tadalafil or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient, wherein said solid dispersion comprises tadalafil in substantially crystalline state. The invention also relates to a process of preparing a solid dispersion of crystalline tadalafil and composition of tadalafil comprising solid dispersion.
In context of the invention, terms like "active" or "active ingredient" or "drug" or "drug substance" or "pharmacologically active agent" or "active substance" may be used interchangeably and synonymously for tadalafil or its pharmaceutically acceptable salts thereof.
The term "compositions" as used herein refers to dosage form for oral administration in the form of tablets, capsules, pills, powders, granules, particles, pellets, beads, or mini-tablets.
The term "dispersion" or "solid dispersion" as used herein is defined as a system in a solid state that comprises at least two components, wherein one component is dispersed substantially evenly throughout the other component or components. It may be used interchangeably and synonymously for "pre-mix" or "admixture" or "composite" or "solid composite" to name a few.
The term "crystalline," as used herein, means having a physical state that is a regular three-dimensional array of atoms, ions, molecules or molecular assemblies.
The term "amorphous," as used herein, means a physical state without having regular arrangement of atoms, ions, molecules or molecular assemblies i.e., an unorganized structure.
"Substantially crystalline state" according to the invention refers that recognizable characteristic crystalline tadalafil peaks are present in an X-ray powder diffraction pattern of the solid dispersion and/ or the compositions containing said solid dispersion.
Solid dispersion is a well known method for enhancement of solubility and dissolution of poorly soluble drugs. The solid dispersion of the present invention may be prepared by a number of techniques including solvent evaporation, melt adsorption, fusion, spray drying, spray granulation, spray freezing, spray congealing, melt extrusion, and supercritical fluid precipitation etc.
According to an embodiment of the invention, preferred method of preparing the solid dispersion comprising tadalafil and atleast one pharmaceutical excipient is by spray granulation or solvent evaporation technique. The method involves atomization of the feed solution or suspension in the chamber of a fluid bed-type processor or a pan-coater which is charged with inert filler material. During drying the -filler becomes agglomerated and/or coated and/or layered by the in-situ formation of the solid dispersion by evaporation or spray-drying of the feed solution or dispersion comprising tadalafil. Either of the bottom spray mode or a top spray mode can be used.
The solid dispersion prepared according to an embodiment of the invention is formulated in to suitable dosage forms by methods known in the art.
The composition according to an embodiment of the invention in addition to the active ingredient may comprise one or more pharmaceutically acceptable excipients which include, but are not limited to diluents, lubricants, binders, surfactants, film-formers, plasticizers, coloring agents, flavoring agents, sweetening agents, preservatives, antioxidants and the like.
Diluents used include, but not limited to microcrystalline cellulose (MCC), silicified MCC, lactose, starch, pregelatinized starch, mannitol, sorbitol, dextrates, dextrin, calcium carbonate, calcium sulfate, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, magnesium carbonate, magnesium oxide and the like. Binders used include, but not limited to acacia, alginic acid, carbomer copolymer, carbomer interpolymer, copovidone, microcrystalline cellulose, dextrin, ethylcellulose, gelatin, glucose (liquid), guar gum, hydroxypropyl cellulose, maltose, methylcellulose, polyethylene oxide, polyvinylpyrrolidone, povidone, starch, or sodium carboxymethylcellulose and the like. Surfactants used include, but not limited to (a) nonionic surfactants such as polyoxyethylene fatty alcohol ethers, sorbitan fatty acid esters, polyoxyethylene fatty acid esters, sorbitan esters, glycerol monostearate, polyethylene glycols, cetyl alcohol, cetostearyl alcohol, stearyl alcohol, poloxamers, polaxamines (b) anionic surfactants such as potassium laurate, triethanolamine stearate, sodium lauryl sulfate, alkyl polyoxyethylene sulfates, dioctyl sodium sulfosuccinate, negatively charged phospholipids and negatively charged glyceryl esters (c) cationic surfactants such as quaternary ammonium compounds, benzalkonium chloride, cetyltrimethylammonium bromide, chitosans and lauryldimethylbenzylammonium chloride. Lubricants used include, but not limited to colloidal silicon dioxide, talc, stearic acid and its salts.
Suitable solvents that may be used for preparing the dispersion include organic, aqueous, or a mixture thereof. Organic solvents may be aliphatic alcohols such as methanol, ethanol, n-propanol, and isopropanol; aliphatic ketones such as acetone and methyl ethyl ketone; aliphatic carboxylic esters such as ethyl acetate; aromatic hydrocarbons such as toluene and xylene; aliphatic hydrocarbons such as hexane; aliphatic nitriles such as acetonitrile; chlorinated hydrocarbons such as dichloromethane; aliphatic sulfoxides such as dimethyl sulfoxide; and the like, as well as mixtures comprising at least one of the foregoing organic solvents.
Aqueous solvents include solvent comprising water and/or a water-miscible organic solvent such as a lower alcohol, acetonitrile, tetrahydrofuran, dimethylacetamide, dimethyl formamide, and the like. Combination of various solvents can also be used.
The tablets may be optionally coated with a film former that comprises polymers such as cellulose derivatives or other commercially available coating compositions such as Instacoat™, Opadry™ etc.
The invention also relates to process for preparing tadalafil compositions comprising crystalline tadalafil solid dispersion or its pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient, wherein, said process comprises the steps of: i) Preparing granulate comprising tadalafil dispersion along with at least one filler and optionally other excipients, by wet granulation; ii) Drying said granulate;
iii) Blending said granulate of step (ii) with extra-granular excipient; iv) Compressing said blended granulate of step (iii) to get the tablet; and
v) Optionally coating said tablet with a film coating material.
Determination of phase conversion of tadalafil either in pure form or in the pharmaceutical compositions comprising the dispersions of said drug can be determined by using analytical techniques like X-ray diffraction analysis, differential scanning calorimetry, optical microscopy etc. The invention uses X- ray diffraction analysis to determine the physical form of the drug in pure form as well as in the composition.
The following examples illustrate specific aspects and embodiments of the invention and demonstrate the practice and advantages thereof. It is to be understood that the examples are given by way of illustration only and are not intended to limit the scope of the invention in any manner.
Composition for Tadalafil Solid Composite:
Brief Manufacturing Process:
1 . Add Tadalafil, Sodium lauryl sulfate and Povidone in Dimethyl sulfoxide and Acetone solvent mixture under stirring to form solution.
2. Disperse poloxamer 188 to step-1 under stirring.
3. Remove the solvent to get solid composite.
Example-2
Unit Composition:
1. Add tadalafil, sodium lauryl sulfate and povidone in a mixture of acetone and dimethyl sulfoxide solvent under stirring.
2. Add poloxamer to step-1 under stirring.
3. Granulate lactose using step-2 dispersion.
4. Add microcrystalline cellulose, croscarmellose sodium & colloidal silicon dioxide to step-3 granulates and blends.
5. Lubricate the step-4 materials using Magnesium stearate.
6. Compress the step-5 blend to tablet.
Example-3
Unit Composition:
1. Add Tadalafil, Sodium lauryl sulfate and Povidone in Dimethyl sulfoxide and Acetone solvent mixture under stirring to form solution.
2. Disperse poloxamer 188 to step-1 under stirring.
3. Granulate lactose using step-2 dispersion in Fluid bed processor.
4. Add microcrystalline cellulose, croscarmellose sodium & Colloidal silicon dioxide to step-3 granules and blend.
5. Lubricate the step-4 materials using Magnesium stearate.
6. Compress the step-5 blend to tablet.
7. Disperse Opadry™ or Instacoat™ in water and film coat the step-6 core tablets.
Dissolution Study:
The composition as disclosed in Example 2 & 3 comprising the dispersion of crystalline tadalafil were studied for drug release in 1000 ml of aqueous media, containing 0.25 wt% sodium lauryl at 37°C, USP apparatus II (paddle) rotating at a speed of 25 rpm; and the results are tabulated in Table 1 given below:
Table 1
Claims
1. A solid dispersion comprising tadalafil or its pharmaceutically acceptable salts thereof and optionally other pharmaceutically acceptable excipients, wherein said tadalafil is substantially in crystalline state.
A pharmaceutical composition comprising solid dispersion of tadalafil or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient, wherein said solid dispersion comprises tadalafil in substantially crystalline state.
A process for preparing solid dispersion comprising tadalafil or its pharmaceutically acceptable salts thereof in substantially crystalline state and optionally other pharmaceutically acceptable excipients, wherein said process comprises the steps of:
i. Dissolving/ Dispersing tadalafil, and one or more pharmaceutically acceptable excipients in a solvent to get a solution/ dispersion; and
ii. Drying said solution/ dispersion of step (i) to get the solid dispersion of tadalafil.
A process for preparing a pharmaceutical composition comprising crystalline tadalafil solid dispersion and at least one pharmaceutically acceptable excipient, wherein said process involves the following steps:
i. Preparing granulate comprising tadalafil dispersion along with at least one filler and optionally other excipients, by wet granulation;
ii. Drying said granulate; iii. Blending said granulate of step (ii) with extra-granular excipient;
iv. Compressing said blended granulate of step (iii) to get the tablet; and
v. Optionally coating said tablet with a film coating material.
The solid dispersion according to claim 1, wherein said excipient is selected from a group consisting of binders, surfactants, and hydrophilic polymers or combinations thereof.
The process according to claim 3, wherein said solvent is selected from a group consisting of acetone, dimethylsulfoxide, isopropyl alcohol, dimethylformamide, dichloromethahe, ethanol, methanol, methyl ethyl ketone, ethyl acetate, acetonitrile, and combinations thereof.
The process according to claim 3, wherein said drying is carried out by evaporation or spray drying or spray granulation of the solution or dispersion comprising tadalafil.
The excipient according to claim 2 or 4, is selected from a group consisting of fillers, diluents, binders, disintegrants, lubricants, glidants or their combinations thereof.
A solid dispersion of tadalafil having the following ingredients:
10. A pharmaceutical composition of tadalafil having the following ingredients per unit:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3649/CHE/2010 | 2010-12-02 | ||
IN3649CH2010 | 2010-12-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012085927A2 true WO2012085927A2 (en) | 2012-06-28 |
WO2012085927A3 WO2012085927A3 (en) | 2012-09-07 |
Family
ID=46314546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2011/000820 WO2012085927A2 (en) | 2010-12-02 | 2011-12-01 | Tadalafil compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012085927A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014003677A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising solid dispersion particles containing tadalafil |
WO2014125343A1 (en) * | 2013-02-12 | 2014-08-21 | Alembic Pharmaceuticals Limited | Tadalafil tablet composition with reduced dose strength |
CN104188912A (en) * | 2014-07-17 | 2014-12-10 | 山东大学 | Tadalafil solid dispersion and tablet thereof |
WO2014202797A1 (en) * | 2013-07-05 | 2014-12-24 | Synthon B.V. | Pharmaceutical composition comprising a solid dispersion of tadalafil |
CN105496963A (en) * | 2015-11-24 | 2016-04-20 | 浙江华海药业股份有限公司 | A tadalafil solid dispersoid and a preparing method of a medicine preparation of the tadalafil solid dispersoid |
US20170020880A1 (en) * | 2015-07-22 | 2017-01-26 | Hetero Research Foundation | Pharmaceutical compositions of trametinib |
TWI586379B (en) * | 2015-06-29 | 2017-06-11 | 永信藥品工業股份有限公司 | Method of preparing very slightly soluble drug with solid dosage form |
CN107334737A (en) * | 2017-07-21 | 2017-11-10 | 广州中医药大学 | Tadalafei solid dispersion system and preparation method thereof |
WO2018102572A1 (en) * | 2016-11-30 | 2018-06-07 | Druggability Technologies Ip Holdco Limited | Pharmaceutical formulation containing tadalafil |
JP2021513568A (en) * | 2018-02-07 | 2021-05-27 | スマヴァ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングSmaWa GmbH | Pharmaceutical products, manufacturing methods of pharmaceutical products, and drugs containing them |
WO2021145831A1 (en) * | 2020-01-16 | 2021-07-22 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Pharmaceutical compositions comprising tadalafil and relevant excipients |
CN114028349A (en) * | 2021-10-12 | 2022-02-11 | 南京恒正药物研究院有限公司 | Tadalafil orally disintegrating tablet |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996038131A1 (en) * | 1995-06-02 | 1996-12-05 | Glaxo Group Limited | Method of producing a solid dispersion of a poorly water soluble drug |
WO2001008688A2 (en) * | 1999-08-03 | 2001-02-08 | Lilly Icos Llc | Beta-carboline drug products |
WO2008000042A1 (en) * | 2006-06-30 | 2008-01-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
WO2008005039A1 (en) * | 2006-07-07 | 2008-01-10 | Teva Pharmaceutical Industries Ltd. | Solid compositions comprising tadalafil and at least one carrier |
-
2011
- 2011-12-01 WO PCT/IN2011/000820 patent/WO2012085927A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996038131A1 (en) * | 1995-06-02 | 1996-12-05 | Glaxo Group Limited | Method of producing a solid dispersion of a poorly water soluble drug |
WO2001008688A2 (en) * | 1999-08-03 | 2001-02-08 | Lilly Icos Llc | Beta-carboline drug products |
WO2008000042A1 (en) * | 2006-06-30 | 2008-01-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
WO2008005039A1 (en) * | 2006-07-07 | 2008-01-10 | Teva Pharmaceutical Industries Ltd. | Solid compositions comprising tadalafil and at least one carrier |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014003677A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising solid dispersion particles containing tadalafil |
WO2014125343A1 (en) * | 2013-02-12 | 2014-08-21 | Alembic Pharmaceuticals Limited | Tadalafil tablet composition with reduced dose strength |
RU2673228C2 (en) * | 2013-07-05 | 2018-11-23 | Синтон Б.В. | Pharmaceutical composition comprising a solid dispersion of tadalafil |
WO2014202797A1 (en) * | 2013-07-05 | 2014-12-24 | Synthon B.V. | Pharmaceutical composition comprising a solid dispersion of tadalafil |
CN104188912A (en) * | 2014-07-17 | 2014-12-10 | 山东大学 | Tadalafil solid dispersion and tablet thereof |
TWI586379B (en) * | 2015-06-29 | 2017-06-11 | 永信藥品工業股份有限公司 | Method of preparing very slightly soluble drug with solid dosage form |
US10137126B2 (en) | 2015-06-29 | 2018-11-27 | Yung Shin Pharm. Ind. Co., Ltd. | Method of preparing very slightly soluble drug with solid dosage form |
US20170020880A1 (en) * | 2015-07-22 | 2017-01-26 | Hetero Research Foundation | Pharmaceutical compositions of trametinib |
CN105496963A (en) * | 2015-11-24 | 2016-04-20 | 浙江华海药业股份有限公司 | A tadalafil solid dispersoid and a preparing method of a medicine preparation of the tadalafil solid dispersoid |
WO2018102572A1 (en) * | 2016-11-30 | 2018-06-07 | Druggability Technologies Ip Holdco Limited | Pharmaceutical formulation containing tadalafil |
CN110035756A (en) * | 2016-11-30 | 2019-07-19 | 成药技术Ip控股有限公司 | Medicament preparation containing Tadalafei |
US10500202B2 (en) | 2016-11-30 | 2019-12-10 | Druggability Technologies Ip Holdco Limited | Pharmaceutical formulation containing tadalafil |
CN107334737A (en) * | 2017-07-21 | 2017-11-10 | 广州中医药大学 | Tadalafei solid dispersion system and preparation method thereof |
JP2021513568A (en) * | 2018-02-07 | 2021-05-27 | スマヴァ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングSmaWa GmbH | Pharmaceutical products, manufacturing methods of pharmaceutical products, and drugs containing them |
JP7312198B2 (en) | 2018-02-07 | 2023-07-20 | スマヴァ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Pharmaceutical formulations, methods for producing pharmaceutical formulations, and pharmaceuticals containing the same |
WO2021145831A1 (en) * | 2020-01-16 | 2021-07-22 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Pharmaceutical compositions comprising tadalafil and relevant excipients |
CN114028349A (en) * | 2021-10-12 | 2022-02-11 | 南京恒正药物研究院有限公司 | Tadalafil orally disintegrating tablet |
Also Published As
Publication number | Publication date |
---|---|
WO2012085927A3 (en) | 2012-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012085927A2 (en) | Tadalafil compositions | |
US20200163882A1 (en) | Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists | |
KR101737250B1 (en) | Pharmaceutical composition with improved bioavailability | |
WO2017170858A1 (en) | Oral preparation having exceptional elutability | |
EP2621471A2 (en) | Pharmaceutical composition comprising deferasirox | |
JP2001527044A (en) | Itraconazole Oral Formulation and Method for Producing the Same | |
JP4673745B2 (en) | Solid preparation | |
WO2008077591A2 (en) | Pharmaceutical formulation comprising neurokinin antagonist | |
JP2018510221A (en) | PARP inhibitor solid pharmaceutical dosage form and use thereof | |
US20220056012A1 (en) | Amorphous form of a malt1 inhibitor and formulations thereof | |
TWI780270B (en) | Solid dispersion | |
EP3601277B1 (en) | Pharmaceutical formulation | |
WO2021220295A1 (en) | Immediate release pharmaceutical compositions comprising palbociclib | |
JP2019536787A (en) | Pharmaceutical preparations containing tadalafil | |
RU2767872C2 (en) | Pharmaceutical composition and method for its preparation | |
EP2654723B1 (en) | Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof | |
WO2017149550A1 (en) | Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide | |
CN113490492A (en) | Amorphous solid dispersion of pyrazolylamide compound | |
WO2012095151A1 (en) | Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof | |
WO2022029798A1 (en) | Pharmaceutical compositions comprising ribociclib | |
WO2023195018A1 (en) | Solid dispersions of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one | |
JP2813792B2 (en) | Preparation for oral administration of irsogladine maleate and its production method | |
JP2021066715A (en) | Method for producing particle containing imidafenacin and use thereof | |
JP5321454B2 (en) | Manufacturing method of pharmaceutical tablets | |
WO2019239432A1 (en) | Trisodium sacubitril valsartan complex and hot-melt extruded pharmaceutical composition comprising thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11850989 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11850989 Country of ref document: EP Kind code of ref document: A2 |